Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Aduro BioTech Inc (NASDAQ: ADRO) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Aduro BioTech Inc (NASDAQ: ADRO) concerning whether a series of statements by Aduro BioTech Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On May 16, 2016, pre-market, Aduro BioTech revealed that its pancreatic cancer drug missed the main endpoint in a Phase 2b clinical trial. The CRS-207 therapy that was tested both alone and in combination with GVAX Pancreas and was proposed for patients with cancer who had unsuccessfully undergone two prior metastatic treatments. Aduro BioTech 's chairman, Stephen Isaacs, called the findings "unexpected" in light of "the divergence of these data from the results of our Phase 2a study."

On this news, NASDAQ: ADRO shares fell as much as 32% during intraday trading on May 16, 2016.

Based in Berkeley, CA, and founded in 2000 Aduro BioTech Inc focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases.

If you purchased shares of Aduro BioTech Inc (NASDAQ: ADRO) on or before May 16, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185